The application of plasma 1,5-anhydro-D-glucitol for monitoring type 2 diabetic patients

• Published in: Disease markers Vol. 21; no. 3; pp. 127 - 132
• Main Authors: Dworacka, Marzena, Winiarska, Hanna
• Format: Journal Article
• Language: English
• Published: United States IOS Press 2005
• Subjects: Adult; Aged; Blood Glucose - metabolism; Blood Glucose Self-Monitoring; Cardiovascular System - pathology; Deoxyglucose - blood; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Female; Glucose - metabolism; Glycated Hemoglobin A - biosynthesis; Humans; Male; Middle Aged; Multivariate Analysis; Other; Regression Analysis
• ISSN: 0278-0240; 1875-8630
• DOI: 10.1155/2005/251068

Recent data have suggested that effective control of postprandial blood glucose can reduce the risk of macroangiopathic complications of diabetes, especially cardiovascular risk. 1,5-Anhydro-D-glucitol (1,5-AG) has been proposed as a marker of short-term hyperglycaemic excursions. We aimed to evaluate its usefulness in patients with type 2 diabetes and have attempted to indicate when 1,5-AG monitoring should be used in ordinary diabetes care settings. The study group consisted of 130 type 2 diabetic patients aged 36-69 years. 1,5-AG plasma level, HbA_1c concentrations and daily glucose profile were measured. Mean blood glucose (MBG), M-value were calculated and maximal daily glycaemia (MxG) was established as indicators of short-term hyperglycaemic episodes. 1,5-AG plasma level was negatively and HbA_1c was positively correlated with fasting glycaemia (FG), MBG, M-value and MxG. Multivariate regression analysis revealed that 1,5-AG plasma level is determined by MxG only, while FG determined HbA_1c concentration in blood. The analysis of 1,5-AG level and HbA_1c distributions in well and poorly controlled patients revealed that persons with low HbA_1c values may have decreased 1,5-AG plasma level. 1,5-AG plasma level monitoring is the useful method to identify well controlled, exclusively based on HbA_1c levels type 2 diabetic patients with transient hyperglycaemia, accordingly patients at high risk of macroangiopathic complications.